Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young Adults

Journal of Pediatric Oncology Nursing

Volumn 30, Issue 2, 2013, Pages 63-77

  Shinnick, Sara E ^a   Browning, Mary L ^a   Koontz, Susannah E ^b  

^a Sigma Tau Pharmaceuticals Inc   (United States)

^b Koontz Oncology Consulting LLC   (United States)

Author keywords

acute lymphoblastic leukemia; allergic reactions; asparaginase; hypersensitivity

Indexed keywords

EID: 84875313529     PISSN: 10434542     EISSN: 15328457     Source Type: Journal    
DOI: 10.1177/1043454212471728     Document Type: Review

References (55)

1. Abbas A. K.,Lichtman A. H.Cellular and molecular immunology. 2003). Cellular and molecular immunology (5th ed.). Philadelphia, PA: Saunders.Philadelphia, PA: Saunders; 2003:.
2. Asselin B. L.The right dose for the right patient.Blood. 2012;119:1617-1618.
3. AsselinB. L.KreissmanS.CoppolaD. J.BernalS. D.LeavittP. R.GelberR. D CohenH. J. (1999). Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology, 21, 6-12. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10029805.
4. Asselin B. L.,Whitin J. C.,Coppola D. J.,Rupp I. P.,Sallan S. E.,Cohen H. J.Comparative pharmacokinetic studies of three asparaginase preparations.Journal of Clinical Oncology. 1993;11:1780-1786.
5. August K.,Miller W.,Dalton S.,Shinnick S Poster session presented at the meeting of American Society of Pediatric Hematology Oncology, Montreal; 2010Canada; 2010.
6. Avramis V. I.,Avramis E. V.,Hunter W.,Long M. C.Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).Anticancer Research. 2009;29:299-302.
7. AvramisV. I.PanosyanE. H. (2005). Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clinical Pharmacokinetics, 44, 367-393. Retrieved from http://adisonline.com.proxy.lib.mcw.edu/pharmacokinetics/Abstract/2005/44040/Pharmacokinetic_Pharmacodynamic_Relationships_of.3.aspx.
8. Avramis V. I.,Sencer S.,Periclou A. P.,Sather H.,Bostrom B. C.,Cohen L. J.,Holcenberg J. S.A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study.Blood. 2002;99:1986-1994.
9. Avramis V. I.,Tiwari P. N.Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.International Journal of Nanomedicine. 2006;1:241-254.
10. Capizzi R. L.Asparaginase revisited.Leukemia & Lymphoma. 1993;10:147-150.
11. Carroll W. L.,Raetz E. A.Clinical and laboratory biology of childhood acute lymphoblastic Leukemia.Journal of Pediatrics. 2012;160:10-18.
12. Chen S.-H.,Pei D.,Yang W.,Cheng C.,Jeha S.,Cox N. J.,Relling M. V.Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.Clinical Pharmacology & Therapeutics. 2010;88:191-196.
13. Dinndorf P. A.,Gootenberg J.,Cohen M. H.,Keegan P.,Pazdur R.FDA drug approval summary: Pegaspargase (Oncaspar®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).The Oncologist. 2007;12:991-998.
14. Douer D.,De Angelo D.De Angelo D.New approaches for the treatment of young adults with ALL. Boston, MA: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School; 2008:.
15. EUSA Pharma, Inc (2011, November). Asparaginase Erwinia chrysanthemi ERWINAZE prescribing information. Langhorne, PA: Author. Retrieved from http://www.erwinaze.com/hcp/index.html.
16. Gaynon P. S.,Angiolillo A. L.,Carroll W. L.,Nachman J. B.,Trigg M. E.,Sather H. N.,Devidas M.Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report.Leukemia. 2010;24:285-297.
17. Graham M. L.Pegaspargase: A review of clinical studies.Advanced Drug Delivery Reviews. 2003;55:1293-1302.
18. Hunger S.Parental and oral chemotherapy administration guidelines used by the Children's Oncology Group. Acadia, CA: Archives of the Children's Oncology Group; 2010:.
19. Jeha S.,Pui C.-H.,Relling M. V.,Evans W. E.,Cheng C.,Boyett J. M.,Zhou Y.Total therapy study for XVI for newly diagnosed patients with acute lymphoblastic leukemia. Memphis, TN: Archives of St. Jude Children's Research Hospital, Departments of Oncology, Pharmacology Sciences, Infections Diseases, Biostatistics, Pathology, and Radiological Sciences; 2007:.
20. Kang C.,Xu W.,Wilson M.,He B.,Miller N. W.,Bengten E.,Cerutti A.Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils.Nature Immunology. 2009;10:889-898.
21. Körholz D.,Wahn U.,Jürgens H.,Wahn V.Allergic reactions in treatment with l-asparaginase: Significance of specific IgE antibodies.Monatsschrift Kinderheilkunde. 1990;138:23-25.
22. Liu C.,Kawedia J. D.,Cheng C.,Pei D.,Fernandez C. A.,Cai X.,Relling M. V.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Leukemia. 2012;:.
23. Lundbeck Inc. (2010). Elspar (asparaginase) prescribing information. Deerfield, IL: Author. Retrieved from http://www.lundbeck.com/upload/us/files/pdf/Products/Elspar_PI_US_EN.pdf.
24. Masetti R.,Pession A.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Biologics: Targets & Therapy. 2009;3:359-368.
25. Medac Hematology. (2009, November). Standard information for pharmacists-Oncaspar. Wedel, Germany: Author. Retrieved from http://www.medac-sk.eu/file.php?id=124.
26. Moghrabi A.,Levy D. E.,Asselin B.,Barr R.,Clavell L.,Hurwitz C.,Silverman L. B.Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 5-01 for children with acute lymphoblastic leukemia.Blood. 2007;109:896-904.
27. Müller H. J.,Boos J.Use of l-asparaginase in childhood ALL.Critical Reviews in Oncology/Hematology. 1998;28:97-113.
28. Nesbit M.,Chard R.,Evans A.,Karon M.,Hammond G. D.Evaluation of intramuscular versus intravenous administration of l-asparaginase in childhood leukemia.American Journal of Pediatric Hematology/Oncology. 1979;1:9-13.
29. Ohnuma T.,Holland J. F.,Meyer P.Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.Cancer. 1972;30:376-381.
30. Pagani M.The complex clinical picture of presumably allergic side effects to cytostatic drugs: Symptoms, pathomechanism, reexposure, and desensitization.Medical Clinics of North America. 2010;94:835-852.
31. Panetta J. C.,Gajjar A.,Hijiya N.,Hak L. J.,Cheng C.,Liu W.,Relling M. V.Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.Clinical Pharmacology & Therapeutics. 2009;86:651-658.
32. PanosyanE. H.SeibelN. L.Martin-AragonS.GaynonP. S.AvramisI. A.SatherH.AvramisV. I. (2004). Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology, 26, 217-226. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15087948.
33. Petersen W.,Clark D.,Senn S.,Cash T.,Keller F.,Lew G.Pegaspargase administration in children with acute lymphoblastic leukemia. Montreal, Canada: Poster session presented at the meeting of the American Society of Pediatric Hematology Oncology; 2012:.
34. Pidparti M.,Bostrom B.Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly.Pediatric Blood & Cancer. 2011;56:458-459.
35. Pieters R.,Hunger S. P.,Boos J.,Rizzari C.,Silverman L.,Baruchel A.,Pui C. H.l-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase.Cancer. 2011;117:238-249.
36. Pui C. H.,Carroll W. L.,Meshinchi S.,Arceci R. J.Biology, risk stratification, and therapy of pediatric acute leukemias: An update.Journal of Clinical Oncology. 2011;29:551-565.
37. Pui C. H.,Evans W. E.Treatment of acute lymphoblastic leukemia.New England Journal of Medicine. 2006;354:166-178.
38. Sigma-Tau Pharmaceuticals, Inc. (2011, May). Oncaspar (pegaspargase) prescribing information. Gaithersburg, MD. Retrieved from http://www.oncaspar.com/providers.asp.
39. Silverman L. B.,Armstrong S.,Cohen L.,Fleming M.,Fletcher J.,Gilliland D.,Waber D.DFCI 00-001 Pediatric ALL. Boston, MA: Archives of Dana Farber Cancer Institute, Department of Pediatric Leukemia; 2006:.
40. Silverman L. B.,Gelber R. D.,Kimball Dalton V.,Asselin B. L.,Barr R. D.,Clavell L. A.,Sallan S. E.Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01.Blood. 2001;97:1211-1218.
41. Silverman L. B.,Stevenson K.,Vrooman L. M.,Supko J. G.,Asselin B.,Athale U.,Sallan S. E.Randomized comparison of IV peg and IM E. coli asparaginase in children and adolescents with acute lymphoblastic leukemia: Results of the DFCI ALL consortium protocol 05-01. Paper presented at the 53rd ASH Annual Meeting and Exposition; 2011Atlanta, GA; 2011
42. Sompayrac L.How the immune system works. 2008). How the immune system works (3rd ed.). Malden, MA: Blackwell.Malden, MA: Blackwell; 2008:.
43. Steiner M.,Hochreiter D.,Kasper D. C.,Kornmüller R.,Pichler H.,Haas O. A.,Attarbaschi A.Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.Leukemia & Lymphoma. 2012;53:1682-1687.
44. Stock W.,Douer D.,DeAngelo D. J.,Arellano M.,Advani A.,Damon L.,Bleyer A.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel.Leukemia & Lymphoma. 2011;52:2237-2253.
45. Strullu M.,Corradini N.,Audrain M.,Orsonneau J.,Bouige D.,Thomare P.,Méchinaud F.Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.Leukemia & Lymphoma. 2010;51:1464-1472.
46. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program. (2006). Common terminology criteria for adverse events (CTCAE), Version 3.0: Allergy/ Immunology. Retrieved from http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
47. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program. (2010). Common terminology criteria for adverse events (CTCAE), Version 4.0: Allergy/Immunology. Retrieved from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
48. US Department of Health and Human Services, National Institute of Health, National Cancer Institute. (2012). Surveillance epidemiology and end results-SEER stat fact sheets: Acute lymphocytic leukemia. Retrieved from http://seer.cancer.gov/statfacts/html/alyl.html.
49. Vrooman L. M.,Supko J. G.,Neuberg D. S.,Asselin B. L.,Athale U. H.,Clavell L.,Silverman L. B.Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Pediatric Blood & Cancer. 2010;54:199-205.
50. Wade H. E.,Elsworth R.,Herberg D.,Keppie J.,Sargeant K.A new l-asparaginase with antitumor activity?.Lancet. 1968;2:776-777.
51. Wetzler M.,Sanford B.,Kurtzberg J.,DeOliveira D.,Frankel S.,Powell B.,Larson R.Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.Blood. 2007;109:4164-4167.
52. Willer A.,Gerss J.,König T.,Franke D.,Kühnel H. J.,Henze G.,Lanvers-Kaminsky C.Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials.Blood. 2011;118:5774-5782.
53. Woo M. H.,Hak L. J.,Storm M. C.,Evans W. E.,Sandlund J. T.,Rivera G. K.,Relling M. V.Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.Leukemia. 1998;12:1527-1533.
54. WooM. H.HakL. J.StormM. C.SandlundJ. T.RibeiroR. C.RiveraG. K.RellingM. V. (2000). Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 18, 1525-1532. Retrieved from http://jco.ascopubs.org.proxy.lib.mcw.edu/content/18/7/1525.long.
55. Zalewska-Szewczyk B.,Andrzejewski W.,Młynarski W.,Jedrychowska-Dańska K.,Witas H.,Bodalski J.The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.Leukemia & Lymphoma. 2007;48:931-936.